Zhang Yuyang, Zhang Wei, Dai Yutian, Jiang Hui, Zhang Xiansheng
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Province, China; Institute of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Province, China; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Anhui Province, China.
Department of Andrology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Sex Med. 2021 Jun;9(3):100356. doi: 10.1016/j.esxm.2021.100356. Epub 2021 May 26.
The association between folic acid (FA) and erectile dysfunction (ED) was contradictory in the published original articles, and no meta-analysis was conducted to pool these data.
To verify the role of FA in the pathology of ED and explore the treatment efficacy of FA for ED patients.
An extensive search was performed on PubMed, Cochrane Library, and Web of Science to obtain all relevant studies published up to October 31, 2020. Studies comparing the serum FA level between ED patients and healthy controls, or comparing the score of the IIEF-5, or IIEF before and after folic acid therapy alone or combination in ED patient were eligible for our meta-analysis. The Newcastle-Ottawa Scales (NOS) was used to qualify included studies.
The standardized mean differences (SMD) and their corresponding 95% confidence intervals (95% CIs) were calculated to pool our data.
Nine studies were eligible for our meta-analysis to verify the association between FA and ED, and to explore the treatment efficacy of FA for ED patients. The pooled SMD of the FA level difference between ED patients and healthy subjects was -0.94 (95% CI: -1.59, -0.30, P = .004). Moreover, the level of folic acid in healthy subjects, Mild ED patients, Moderate ED patients and Severe ED patients was 11.847 (95%CI = 9.671, 14.022), 9.496 (95%CI = 8.425, 10.567), 6.597 (95%CI = 5.187, 8.007) and 5.623 (95%CI = 3.535, 7.711) respectively. The SMD of changes in score of IIEF-5 was 1.89 with 95%CI (1.60, 2.17) after FA administration in ED patients. Our analysis also showed that combination therapy of FA plus tadalafil changed the score of IIEF with 0.90 (95%CI = 0.44, 1.36) comparing to combination of placebo plus tadalafil.
This novel meta-analysis demonstrated that FA was an independent risk factor for ED and FA supplement may have potentially positive effects in the treatment of ED patients. Zhang Y, Zhang W, Dai Y, et al. Serum Folic Acid and Erectile Dysfunction: A Systematic Review and Meta-Analysis. Sex Med 2021;9:100356.
已发表的原始文章中叶酸(FA)与勃起功能障碍(ED)之间的关联相互矛盾,且未进行荟萃分析来汇总这些数据。
验证FA在ED病理中的作用,并探讨FA对ED患者的治疗效果。
在PubMed、Cochrane图书馆和科学网进行广泛检索,以获取截至2020年10月31日发表的所有相关研究。比较ED患者与健康对照者血清FA水平,或比较单独或联合叶酸治疗前后ED患者国际勃起功能指数(IIEF-5)或IIEF评分的研究符合我们的荟萃分析条件。使用纽卡斯尔-渥太华量表(NOS)对纳入研究进行质量评估。
计算标准化均数差(SMD)及其相应的95%置信区间(95%CI)以汇总数据。
9项研究符合我们的荟萃分析条件,以验证FA与ED之间的关联,并探讨FA对ED患者的治疗效果。ED患者与健康受试者之间FA水平差异的合并SMD为-0.94(95%CI:-1.59,-0.30,P = 0.004)。此外,健康受试者、轻度ED患者、中度ED患者和重度ED患者的叶酸水平分别为11.847(95%CI = 9.671,14.022)、9.496(95%CI = 8.425,10.567)、6.597(95%CI = 5.187,8.007)和5.623(95%CI = 3.535,7.711)。ED患者服用FA后IIEF-5评分变化的SMD为1.89,95%CI为(1.60,2.17)。我们的分析还表明,与安慰剂加他达拉非联合治疗相比,FA加他达拉非联合治疗使IIEF评分变化了0.90(95%CI = 0.44,1.36)。
这项新的荟萃分析表明,FA是ED的独立危险因素,补充FA可能对ED患者的治疗具有潜在的积极作用。张Y,张W,戴Y等。血清叶酸与勃起功能障碍:一项系统评价和荟萃分析。性医学2021;9:100356。